Bavarian Nordic Receives Order from the Canadian Government to Supply Imvamune Smallpox Vaccine

Bavarian Nordic A/S has signed two contracts with the Canadian authorities for the delivery of a total of 65,700 doses of Imvamune smallpox vaccine. The vaccines will be delivered in 2014 and 2015. This will bring the current number of delivered doses of Imavume to Canada above 100,000 doses.

Following a public tender, the Public Health Agency of Canada has awarded Bavarian Nordic a contract to deliver 45,700 doses of Imvamune with the option to deliver an additional 314,300 doses. This contract represents the first commercial contract awarded by the Canadian authorities to Bavarian Nordic after receiving approval of Imvamune by Health Canada in 2013.

Secondly, the Canadian Department of National Defence, through exercise of an option under an ongoing contract, has ordered 20,000 doses of Imvamune smallpox vaccine to replace the current stockpile for the Canadian Armed Forces. This contract was awarded in 2008 with initial deliveries of 20,000 doses in 2009, followed by a replacement order in 2012. Under this contract, an option of an additional 140,000 doses remains.

Paul Chaplin, President & CEO of Bavarian Nordic said: "Having supplied our smallpox vaccine for the armed forces since 2008, we are pleased to continue our collaboration with the Canadian defense to address their biological  preparedness. We are also pleased to supply the first commercial quantities of Imvamune to the Public Health Agency of Canada following the approval in 2013 of Imvamune for use in a public health emergency in individuals who are contraindicated to replicating smallpox vaccines."